Immune infiltration, aggressive pathology, and poor survival outcomes in RECQL helicase deficient breast cancers
Neoplasia. 2023 Dec 21;47:100957. doi: 10.1016/j.neo.2023.100957. Online ahead of print.ABSTRACTRECQL is essential for genomic stability. Here, we evaluated RECQL in 449 pure ductal carcinomas in situ (DCIS), 152 DCIS components of mixed DCIS/invasive breast cancer (IBC) tumors, 157 IBC components of mixed DCIS/IBC and 50 normal epithelial terminal ductal lobular units (TDLUs). In 726 IBCs, CD8+, FOXP3+, IL17+, PDL1+, PD1+ T-cell infiltration (TILs) were investigated in RECQL deficient and proficient cancers. Tumor mutation burden (TMB) was evaluated in five RECQL germ-line mutation carriers with IBC by genome sequencing. ...
Source: Neoplasia - December 22, 2023 Category: Cancer & Oncology Authors: Ayat Lashen Abdulbaqi Al-Kawaz Jennie N Jeyapalan Shatha Alqahtani Ahmed Shoqafi Mashael Algethami Michael Toss Andrew R Green Nigel P Mongan Sudha Sharma Mohammad R Akbari Emad A Rakha Srinivasan Madhusudan Source Type: research
Immune infiltration, aggressive pathology, and poor survival outcomes in RECQL helicase deficient breast cancers
Neoplasia. 2023 Dec 21;47:100957. doi: 10.1016/j.neo.2023.100957. Online ahead of print.ABSTRACTRECQL is essential for genomic stability. Here, we evaluated RECQL in 449 pure ductal carcinomas in situ (DCIS), 152 DCIS components of mixed DCIS/invasive breast cancer (IBC) tumors, 157 IBC components of mixed DCIS/IBC and 50 normal epithelial terminal ductal lobular units (TDLUs). In 726 IBCs, CD8+, FOXP3+, IL17+, PDL1+, PD1+ T-cell infiltration (TILs) were investigated in RECQL deficient and proficient cancers. Tumor mutation burden (TMB) was evaluated in five RECQL germ-line mutation carriers with IBC by genome sequencing. ...
Source: Neoplasia - December 22, 2023 Category: Cancer & Oncology Authors: Ayat Lashen Abdulbaqi Al-Kawaz Jennie N Jeyapalan Shatha Alqahtani Ahmed Shoqafi Mashael Algethami Michael Toss Andrew R Green Nigel P Mongan Sudha Sharma Mohammad R Akbari Emad A Rakha Srinivasan Madhusudan Source Type: research
Immune infiltration, aggressive pathology, and poor survival outcomes in RECQL helicase deficient breast cancers
Neoplasia. 2023 Dec 21;47:100957. doi: 10.1016/j.neo.2023.100957. Online ahead of print.ABSTRACTRECQL is essential for genomic stability. Here, we evaluated RECQL in 449 pure ductal carcinomas in situ (DCIS), 152 DCIS components of mixed DCIS/invasive breast cancer (IBC) tumors, 157 IBC components of mixed DCIS/IBC and 50 normal epithelial terminal ductal lobular units (TDLUs). In 726 IBCs, CD8+, FOXP3+, IL17+, PDL1+, PD1+ T-cell infiltration (TILs) were investigated in RECQL deficient and proficient cancers. Tumor mutation burden (TMB) was evaluated in five RECQL germ-line mutation carriers with IBC by genome sequencing. ...
Source: Neoplasia - December 22, 2023 Category: Cancer & Oncology Authors: Ayat Lashen Abdulbaqi Al-Kawaz Jennie N Jeyapalan Shatha Alqahtani Ahmed Shoqafi Mashael Algethami Michael Toss Andrew R Green Nigel P Mongan Sudha Sharma Mohammad R Akbari Emad A Rakha Srinivasan Madhusudan Source Type: research
Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma
Neoplasia. 2023 Nov 30;47:100951. doi: 10.1016/j.neo.2023.100951. Online ahead of print.ABSTRACTThyroid hormone receptor-interacting protein 13 (TRIP13) is involved in cancer progression, but its role in pancreatic ductal adenocarcinoma (PDAC) is unknown. Thus, we assessed the expression, functional role, and mechanism of action of TRIP13 in PDAC. We further examined the efficacy of TRIP13 inhibitor, DCZ0415, alone or in combination with gemcitabine on malignant phenotypes, tumor progression, and immune response. We found that TRIP13 was overexpressed in human PDACs relative to corresponding normal pancreatic tissues. TRIP...
Source: Neoplasia - December 1, 2023 Category: Cancer & Oncology Authors: Farrukh Afaq Sumit Agarwal Prachi Bajpai Sameer Al Diffalha Hyung-Gyoon Kim Shajan Peter Moh'd Khushman Subhash C Chauhan Priyabrata Mukherjee Sooryanarayana Varambally Upender Manne Source Type: research
Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma
Neoplasia. 2023 Nov 30;47:100951. doi: 10.1016/j.neo.2023.100951. Online ahead of print.ABSTRACTThyroid hormone receptor-interacting protein 13 (TRIP13) is involved in cancer progression, but its role in pancreatic ductal adenocarcinoma (PDAC) is unknown. Thus, we assessed the expression, functional role, and mechanism of action of TRIP13 in PDAC. We further examined the efficacy of TRIP13 inhibitor, DCZ0415, alone or in combination with gemcitabine on malignant phenotypes, tumor progression, and immune response. We found that TRIP13 was overexpressed in human PDACs relative to corresponding normal pancreatic tissues. TRIP...
Source: Neoplasia - December 1, 2023 Category: Cancer & Oncology Authors: Farrukh Afaq Sumit Agarwal Prachi Bajpai Sameer Al Diffalha Hyung-Gyoon Kim Shajan Peter Moh'd Khushman Subhash C Chauhan Priyabrata Mukherjee Sooryanarayana Varambally Upender Manne Source Type: research
Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma
Neoplasia. 2023 Nov 30;47:100951. doi: 10.1016/j.neo.2023.100951. Online ahead of print.ABSTRACTThyroid hormone receptor-interacting protein 13 (TRIP13) is involved in cancer progression, but its role in pancreatic ductal adenocarcinoma (PDAC) is unknown. Thus, we assessed the expression, functional role, and mechanism of action of TRIP13 in PDAC. We further examined the efficacy of TRIP13 inhibitor, DCZ0415, alone or in combination with gemcitabine on malignant phenotypes, tumor progression, and immune response. We found that TRIP13 was overexpressed in human PDACs relative to corresponding normal pancreatic tissues. TRIP...
Source: Neoplasia - December 1, 2023 Category: Cancer & Oncology Authors: Farrukh Afaq Sumit Agarwal Prachi Bajpai Sameer Al Diffalha Hyung-Gyoon Kim Shajan Peter Moh'd Khushman Subhash C Chauhan Priyabrata Mukherjee Sooryanarayana Varambally Upender Manne Source Type: research
Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma
Neoplasia. 2023 Nov 30;47:100951. doi: 10.1016/j.neo.2023.100951. Online ahead of print.ABSTRACTThyroid hormone receptor-interacting protein 13 (TRIP13) is involved in cancer progression, but its role in pancreatic ductal adenocarcinoma (PDAC) is unknown. Thus, we assessed the expression, functional role, and mechanism of action of TRIP13 in PDAC. We further examined the efficacy of TRIP13 inhibitor, DCZ0415, alone or in combination with gemcitabine on malignant phenotypes, tumor progression, and immune response. We found that TRIP13 was overexpressed in human PDACs relative to corresponding normal pancreatic tissues. TRIP...
Source: Neoplasia - December 1, 2023 Category: Cancer & Oncology Authors: Farrukh Afaq Sumit Agarwal Prachi Bajpai Sameer Al Diffalha Hyung-Gyoon Kim Shajan Peter Moh'd Khushman Subhash C Chauhan Priyabrata Mukherjee Sooryanarayana Varambally Upender Manne Source Type: research
Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma
Neoplasia. 2023 Nov 30;47:100951. doi: 10.1016/j.neo.2023.100951. Online ahead of print.ABSTRACTThyroid hormone receptor-interacting protein 13 (TRIP13) is involved in cancer progression, but its role in pancreatic ductal adenocarcinoma (PDAC) is unknown. Thus, we assessed the expression, functional role, and mechanism of action of TRIP13 in PDAC. We further examined the efficacy of TRIP13 inhibitor, DCZ0415, alone or in combination with gemcitabine on malignant phenotypes, tumor progression, and immune response. We found that TRIP13 was overexpressed in human PDACs relative to corresponding normal pancreatic tissues. TRIP...
Source: Neoplasia - December 1, 2023 Category: Cancer & Oncology Authors: Farrukh Afaq Sumit Agarwal Prachi Bajpai Sameer Al Diffalha Hyung-Gyoon Kim Shajan Peter Moh'd Khushman Subhash C Chauhan Priyabrata Mukherjee Sooryanarayana Varambally Upender Manne Source Type: research
Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma
Neoplasia. 2023 Nov 30;47:100951. doi: 10.1016/j.neo.2023.100951. Online ahead of print.ABSTRACTThyroid hormone receptor-interacting protein 13 (TRIP13) is involved in cancer progression, but its role in pancreatic ductal adenocarcinoma (PDAC) is unknown. Thus, we assessed the expression, functional role, and mechanism of action of TRIP13 in PDAC. We further examined the efficacy of TRIP13 inhibitor, DCZ0415, alone or in combination with gemcitabine on malignant phenotypes, tumor progression, and immune response. We found that TRIP13 was overexpressed in human PDACs relative to corresponding normal pancreatic tissues. TRIP...
Source: Neoplasia - December 1, 2023 Category: Cancer & Oncology Authors: Farrukh Afaq Sumit Agarwal Prachi Bajpai Sameer Al Diffalha Hyung-Gyoon Kim Shajan Peter Moh'd Khushman Subhash C Chauhan Priyabrata Mukherjee Sooryanarayana Varambally Upender Manne Source Type: research
Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma
Neoplasia. 2023 Nov 30;47:100951. doi: 10.1016/j.neo.2023.100951. Online ahead of print.ABSTRACTThyroid hormone receptor-interacting protein 13 (TRIP13) is involved in cancer progression, but its role in pancreatic ductal adenocarcinoma (PDAC) is unknown. Thus, we assessed the expression, functional role, and mechanism of action of TRIP13 in PDAC. We further examined the efficacy of TRIP13 inhibitor, DCZ0415, alone or in combination with gemcitabine on malignant phenotypes, tumor progression, and immune response. We found that TRIP13 was overexpressed in human PDACs relative to corresponding normal pancreatic tissues. TRIP...
Source: Neoplasia - December 1, 2023 Category: Cancer & Oncology Authors: Farrukh Afaq Sumit Agarwal Prachi Bajpai Sameer Al Diffalha Hyung-Gyoon Kim Shajan Peter Moh'd Khushman Subhash C Chauhan Priyabrata Mukherjee Sooryanarayana Varambally Upender Manne Source Type: research
Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma
Neoplasia. 2023 Nov 30;47:100951. doi: 10.1016/j.neo.2023.100951. Online ahead of print.ABSTRACTThyroid hormone receptor-interacting protein 13 (TRIP13) is involved in cancer progression, but its role in pancreatic ductal adenocarcinoma (PDAC) is unknown. Thus, we assessed the expression, functional role, and mechanism of action of TRIP13 in PDAC. We further examined the efficacy of TRIP13 inhibitor, DCZ0415, alone or in combination with gemcitabine on malignant phenotypes, tumor progression, and immune response. We found that TRIP13 was overexpressed in human PDACs relative to corresponding normal pancreatic tissues. TRIP...
Source: Neoplasia - December 1, 2023 Category: Cancer & Oncology Authors: Farrukh Afaq Sumit Agarwal Prachi Bajpai Sameer Al Diffalha Hyung-Gyoon Kim Shajan Peter Moh'd Khushman Subhash C Chauhan Priyabrata Mukherjee Sooryanarayana Varambally Upender Manne Source Type: research
Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma
Neoplasia. 2023 Nov 30;47:100951. doi: 10.1016/j.neo.2023.100951. Online ahead of print.ABSTRACTThyroid hormone receptor-interacting protein 13 (TRIP13) is involved in cancer progression, but its role in pancreatic ductal adenocarcinoma (PDAC) is unknown. Thus, we assessed the expression, functional role, and mechanism of action of TRIP13 in PDAC. We further examined the efficacy of TRIP13 inhibitor, DCZ0415, alone or in combination with gemcitabine on malignant phenotypes, tumor progression, and immune response. We found that TRIP13 was overexpressed in human PDACs relative to corresponding normal pancreatic tissues. TRIP...
Source: Neoplasia - December 1, 2023 Category: Cancer & Oncology Authors: Farrukh Afaq Sumit Agarwal Prachi Bajpai Sameer Al Diffalha Hyung-Gyoon Kim Shajan Peter Moh'd Khushman Subhash C Chauhan Priyabrata Mukherjee Sooryanarayana Varambally Upender Manne Source Type: research
Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma
Neoplasia. 2023 Nov 30;47:100951. doi: 10.1016/j.neo.2023.100951. Online ahead of print.ABSTRACTThyroid hormone receptor-interacting protein 13 (TRIP13) is involved in cancer progression, but its role in pancreatic ductal adenocarcinoma (PDAC) is unknown. Thus, we assessed the expression, functional role, and mechanism of action of TRIP13 in PDAC. We further examined the efficacy of TRIP13 inhibitor, DCZ0415, alone or in combination with gemcitabine on malignant phenotypes, tumor progression, and immune response. We found that TRIP13 was overexpressed in human PDACs relative to corresponding normal pancreatic tissues. TRIP...
Source: Neoplasia - December 1, 2023 Category: Cancer & Oncology Authors: Farrukh Afaq Sumit Agarwal Prachi Bajpai Sameer Al Diffalha Hyung-Gyoon Kim Shajan Peter Moh'd Khushman Subhash C Chauhan Priyabrata Mukherjee Sooryanarayana Varambally Upender Manne Source Type: research
Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma
Neoplasia. 2023 Nov 30;47:100951. doi: 10.1016/j.neo.2023.100951. Online ahead of print.ABSTRACTThyroid hormone receptor-interacting protein 13 (TRIP13) is involved in cancer progression, but its role in pancreatic ductal adenocarcinoma (PDAC) is unknown. Thus, we assessed the expression, functional role, and mechanism of action of TRIP13 in PDAC. We further examined the efficacy of TRIP13 inhibitor, DCZ0415, alone or in combination with gemcitabine on malignant phenotypes, tumor progression, and immune response. We found that TRIP13 was overexpressed in human PDACs relative to corresponding normal pancreatic tissues. TRIP...
Source: Neoplasia - December 1, 2023 Category: Cancer & Oncology Authors: Farrukh Afaq Sumit Agarwal Prachi Bajpai Sameer Al Diffalha Hyung-Gyoon Kim Shajan Peter Moh'd Khushman Subhash C Chauhan Priyabrata Mukherjee Sooryanarayana Varambally Upender Manne Source Type: research
Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma
Neoplasia. 2023 Nov 30;47:100951. doi: 10.1016/j.neo.2023.100951. Online ahead of print.ABSTRACTThyroid hormone receptor-interacting protein 13 (TRIP13) is involved in cancer progression, but its role in pancreatic ductal adenocarcinoma (PDAC) is unknown. Thus, we assessed the expression, functional role, and mechanism of action of TRIP13 in PDAC. We further examined the efficacy of TRIP13 inhibitor, DCZ0415, alone or in combination with gemcitabine on malignant phenotypes, tumor progression, and immune response. We found that TRIP13 was overexpressed in human PDACs relative to corresponding normal pancreatic tissues. TRIP...
Source: Neoplasia - December 1, 2023 Category: Cancer & Oncology Authors: Farrukh Afaq Sumit Agarwal Prachi Bajpai Sameer Al Diffalha Hyung-Gyoon Kim Shajan Peter Moh'd Khushman Subhash C Chauhan Priyabrata Mukherjee Sooryanarayana Varambally Upender Manne Source Type: research
